Trials / Terminated
TerminatedNCT01624636
Safety and Tolerability of Intravenous LFG316 in Wet Age-related Macular Degeneration (AMD).
A Multiple Dose, Two-cohort Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of Intravenous LFG316 in Patients With Neovascular Age-related Macular Degeneration
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 1 (actual)
- Sponsor
- Novartis Pharmaceuticals · Industry
- Sex
- All
- Age
- 55 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of successive intravenous (IV) doses of LFG316 in eligible patients with neovascular age-related macular degeneration (AMD)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Placebo | |
| DRUG | LFG316 | |
| DRUG | LFG316 |
Timeline
- Start date
- 2012-12-01
- Primary completion
- 2013-05-01
- Completion
- 2013-05-01
- First posted
- 2012-06-21
- Last updated
- 2020-12-19
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT01624636. Inclusion in this directory is not an endorsement.